NewAmsterdam Pharma (NASDAQ:NAMS) Shares Purchased by Bain Capital Life Sciences Investors LLC

Bain Capital Life Sciences Investors LLC lifted its stake in NewAmsterdam Pharma (NASDAQ:NAMS) by 2.3% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 10,719,110 shares of the company’s stock after acquiring an additional 245,197 shares during the quarter. NewAmsterdam Pharma comprises approximately 32.4% of Bain Capital Life Sciences Investors LLC’s portfolio, making the stock its largest position. Bain Capital Life Sciences Investors LLC owned 0.12% of NewAmsterdam Pharma worth $275,481,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of NAMS. Capital World Investors purchased a new stake in NewAmsterdam Pharma during the 4th quarter worth $26,113,000. Capital International Investors acquired a new position in shares of NewAmsterdam Pharma in the fourth quarter worth about $53,007,000. Marshall Wace LLP boosted its holdings in NewAmsterdam Pharma by 161.9% in the fourth quarter. Marshall Wace LLP now owns 288,446 shares of the company’s stock valued at $7,413,000 after purchasing an additional 178,322 shares during the last quarter. Jump Financial LLC acquired a new stake in NewAmsterdam Pharma during the 4th quarter valued at approximately $653,000. Finally, Barclays PLC increased its holdings in NewAmsterdam Pharma by 120.0% during the 4th quarter. Barclays PLC now owns 16,713 shares of the company’s stock worth $429,000 after purchasing an additional 9,117 shares during the last quarter. Institutional investors and hedge funds own 89.89% of the company’s stock.

NewAmsterdam Pharma Price Performance

NASDAQ:NAMS opened at $16.34 on Monday. The firm has a market capitalization of $1.79 billion, a P/E ratio of -6.28 and a beta of -0.01. The business has a 50 day simple moving average of $19.87 and a 200 day simple moving average of $21.27. NewAmsterdam Pharma has a 12-month low of $14.06 and a 12-month high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The firm had revenue of $12.77 million for the quarter, compared to analyst estimates of $3.30 million. Research analysts anticipate that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

Insider Buying and Selling at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 150,000 shares of the business’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the sale, the chief accounting officer now directly owns 15,000 shares in the company, valued at approximately $305,550. The trade was a 90.91 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director James N. Topper acquired 1,135 shares of the stock in a transaction that occurred on Wednesday, March 26th. The shares were bought at an average price of $22.49 per share, for a total transaction of $25,526.15. Following the purchase, the director now directly owns 3,013,569 shares of the company’s stock, valued at approximately $67,775,166.81. This trade represents a 0.04 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 19.50% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $48.00 price target on shares of NewAmsterdam Pharma in a research note on Tuesday, January 14th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $40.00 price target on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. UBS Group set a $41.00 target price on NewAmsterdam Pharma in a report on Monday, March 3rd. Scotiabank boosted their price target on NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a “sector outperform” rating in a report on Thursday, February 27th. Finally, Needham & Company LLC restated a “buy” rating and set a $42.00 price objective on shares of NewAmsterdam Pharma in a research note on Tuesday, April 8th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $43.33.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.